2017
Phenotypic spectrum of autosomal recessive congenital ichthyosis due to PNPLA1 mutation
Boyden LM, Craiglow BG, Hu RH, Zhou J, Browning J, Eichenfield L, Lim YL, Luu M, Randolph LM, Ginarte M, Fachal L, Rodriguez‐Pazos L, Vega A, Kramer D, Yosipovitch G, Vahidnezhad H, Youssefian L, Uitto J, Lifton RP, Paller AS, Milstone LM, Choate KA. Phenotypic spectrum of autosomal recessive congenital ichthyosis due to PNPLA1 mutation. British Journal Of Dermatology 2017, 177: 319-322. PMID: 28403545, PMCID: PMC5522355, DOI: 10.1111/bjd.15570.Peer-Reviewed Original Research
2013
Topical Tazarotene for the Treatment of Ectropion in Ichthyosis
Craiglow BG, Choate KA, Milstone LM. Topical Tazarotene for the Treatment of Ectropion in Ichthyosis. JAMA Dermatology 2013, 149: 598-600. PMID: 23677086, PMCID: PMC3809825, DOI: 10.1001/jamadermatol.2013.239.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment of ectropionTopical tazaroteneBilateral lower eyelid ectropionGroup of patientsStandard of carePotential treatment optionLower eyelid ectropionPotential effective treatmentTopical retinoidsMedical therapySurgical interventionTreatment optionsEyelid ectropionCosmetic consequencesEffective treatmentCertain subtypesPatientsEctropionPersistent improvementDaily applicationTazaroteneAdditional studiesAdverse effectsRetinoidsIchthyosisSystemic retinoids in the management of ichthyoses and related skin types
DiGiovanna JJ, Mauro T, Milstone LM, Schmuth M, Toro JR. Systemic retinoids in the management of ichthyoses and related skin types. Dermatologic Therapy 2013, 26: 26-38. PMID: 23384018, PMCID: PMC3884695, DOI: 10.1111/j.1529-8019.2012.01527.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSkin typeHigh-dose vitaminMainstay of therapyTeratogenic side effectsSystemic retinoidsTerm retinoidsCareful surveillanceLimit toxicityEffective therapyDemonstrated efficacySide effectsMucous membranesVitamin ASevere ichthyosisSynthetic retinoidsEarly useRetinoidsTherapyVariety of agesSynthetic derivativesEfficacyTreatmentLimited usefulnessAcetretinEtretinate
2011
Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features
Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. International Journal Of Dermatology 2011, 50: 1480-1485. PMID: 22097993, DOI: 10.1111/j.1365-4632.2011.04990.x.Peer-Reviewed Original ResearchConceptsCases of PRPPityriasis rubra pilarisCases of erythrodermaCases of psoriasisHistologic featuresClinical contextCorrect clinical settingPresence of acantholysisHailey-Hailey diseaseLichenoid infiltratePapulosquamous lesionsPemphigus vulgarisFocal acantholysisHistologic cluesErythrodermaDarier's diseaseAcantholysisClinical settingDermatology literatureDiseasePsoriasisBiopsyDifferent causesDiagnosisInfiltrates
1998
Pneumocystis carinii pneumonia complicating methotrexate treatment of pityriasis rubra pilaris
Duncan K, Imaeda S, Milstone L. Pneumocystis carinii pneumonia complicating methotrexate treatment of pityriasis rubra pilaris. Journal Of The American Academy Of Dermatology 1998, 39: 276-278. PMID: 9704846, DOI: 10.1016/s0190-9622(98)70088-x.Peer-Reviewed Case Reports and Technical Notes
1983
Classification and Therapy of Atrophie Blanche
Milstone L, Braverman I, Lucky P, Fleckman P. Classification and Therapy of Atrophie Blanche. JAMA Dermatology 1983, 119: 963-969. PMID: 6651312, DOI: 10.1001/archderm.1983.01650360009005.Peer-Reviewed Original ResearchConceptsAtrophie blancheCommon pathologic eventEndogenous fibrinolytic activityCharacteristic histopathologic featuresPlatelet thrombus formationOcclusion of vesselsMost patientsClinical evolutionHistopathologic featuresPurpuric papulesClinicopathologic entityLower extremitiesPathologic eventsDeep dermisThrombus formationFibrinolytic activityMultiple causesTherapyTreatmentCauseUlcerationPatientsPapulesPathogenesisDisease